# A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

> **NCT06308419** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- Leiomyosarcoma
- Soft-tissue Sarcomas

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-Sirolimus

## Key facts

- **NCT ID:** NCT06308419
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-14
- **Primary completion:** 2029-02-01
- **Final completion:** 2031-02-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06308419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06308419, "A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06308419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*